Chest
Volume 133, Issue 5, May 2008, Pages 1167-1173
Journal home page for Chest

Original Research: Lung Cancer
Timeliness of Care in Veterans With Non-small Cell Lung Cancer

https://doi.org/10.1378/chest.07-2654Get rights and content

Background

Timeliness is an important dimension of quality of care for patients with lung cancer.

Methods

We reviewed the records of consecutive patients in whom non-small cell lung cancer (NSCLC) had been diagnosed between January 1, 2002, and December 31, 2003, at the Veterans Affairs Palo Alto Health Care System. We used multivariable statistical methods to identify independent predictors of timely care and examined the effect of timeliness on survival.

Results

We identified 129 veterans with NSCLC (mean age, 67 years; 98% men; 83% white), most of whom had adenocarcinoma (51%) or squamous cell carcinoma (30%). A minority of patients (18%) presented with a solitary pulmonary nodule (SPN). The median time from the initial suspicion of cancer to treatment was 84 days (interquartile range, 38 to 153 days). Independent predictors of treatment within 84 days included hospitalization within 7 days (odds ratio [OR], 8.2; 95% confidence interval [CI], 2.9 to 23), tumor size of > 3.0 cm (OR, 4.8; 95% CI, 1.8 to 12.4), the presence of additional chest radiographic abnormalities (OR, 3.0; 95% CI, 1.1 to 8.5), and the presence of one or more symptoms suggesting metastasis (OR, 2.6; 95% CI, 1.1 to 6.2). More timely care was not associated with better survival time (adjusted hazard ratio, 1.6; 95% CI, 1.3 to 1.9). However, in patients with SPNs, there was a trend toward better survival time when the time to treatment was < 84 days.

Conclusions

The time to treatment for patients with NSCLC was often longer than recommended. Patients with larger tumors, symptoms, and other chest radiographic abnormalities receive more timely care. In patients with malignant SPNs, survival may be better when treatment is initiated promptly.

Section snippets

Materials and Methods

We retrospectively reviewed the electronic medical records of 129 consecutive patients in whom non-small cell lung cancer (NSCLC) had been diagnosed at the Veterans Affairs Palo Alto Health Care System between January 1, 2002, and December 31, 2003. We collected information about patient characteristics, tumor characteristics, symptoms suggestive of metastasis at the time of presentation, the utilization of imaging tests and other procedures, the dates of diagnosis and first treatment, and

Results

As shown in Table 1, most of the patients were white (83%) and men (98%). The mean age was 67 years (SD, 10 years). The median tumor diameter was 3.2 cm (IQR, 2.0 to 5.0 cm). Most of the patients had adenocarcinoma (51%) or squamous cell carcinoma (30%) histology. The TNM stage distribution of patients included 15% in stage I, 14% in stage II, 33% in stage III, and 37% in stage IV. A minority of patients (18%) presented with an SPN.

Evaluation and Treatment

Nearly all patients underwent chest radiographs (99%) and chest CT scans (98%) during the diagnostic and staging evaluation (Table 2). More than one chest radiograph was performed in 30% of patients, more than one CT scan of the chest was performed in 11% of patients, and more than one positron emission tomography scan was performed in 3% of patients. Patients underwent a variety of diagnostic and staging procedures (Table 2), but few underwent multiple procedures, and preoperative invasive

Clinical Predictors of Timeliness

In bivariate analyses, a shorter time to treatment (ie, less than the median time of 84 days) was seen more frequently in patients with tumor diameters of > 3.0 cm (62% vs 32%, respectively; p = 0.001), in patients with symptoms suggesting metastasis (62% vs 32%, respectively; p = 0.001), in patients with additional abnormalities seen on chest radiography (67% vs 44%, respectively; p = 0.02), and especially in patients who had been admitted to the hospital within 7 days of the initial suspicion

Effect of Timeliness on Survival

The median follow-up time was 270 days (IQR, 134 to 488 days) from the date of initial suspicion, and 147 days (IQR, 42 to 333 days) from the date of treatment. Eighty-seven patients (67%) died during follow-up, and the median survival time (measured from the date of initial suspicion) was 299 days (IQR, 196 to 402 days). As shown in Figure 2, patients treated within 84 days of diagnosis were more likely to die during follow-up than patients who were treated less promptly (80% vs 55%,

Discussion

Timeliness of care is one of six important dimensions of health-care quality, as defined by the Institute of Medicine.1 In this sample of veterans with lung cancer, we found that times to diagnosis and treatment were often longer than the current recommendations dictate. The time to diagnosis was > 2 months (the threshold recommended by the RAND Corporation3) in 40% of patients, and the time from diagnosis to treatment was > 6 weeks in 24% of patients. Clinical factors associated with more

References (32)

  • Pita-FernandezS et al.

    Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer

    J Clin Epidemiol

    (2003)
  • Institute of Medicine, Committee on Quality of Health Care in America

    (2001)
  • Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer

    Thorax

    (1998)
  • ReifelJL

    Lung cancer

    Quality of care for oncologic conditions and HIV: a review of the literature and quality indicators

    (2000)
  • BillingJS et al.

    Delays in the diagnosis and surgical treatment of lung cancer

    Thorax

    (1996)
  • ChristensenED et al.

    The impact of delayed diagnosis of lung cancer on the stage at the time of operation

    Eur J Cardiothorac Surg

    (1997)
  • Cited by (70)

    • Predictors of treatment initiation and mapping the cancer diagnostic pathway: A retrospective observational cohort study of patients with metastatic non-small cell lung cancer

      2022, Cancer Epidemiology
      Citation Excerpt :

      One study found that 38% of all patients with metastatic lung cancer died within 2 months of diagnosis, with 93% of these deaths being attributed to the diagnosed cancer [7]. Early diagnosis hinges on recognition and action on clinical clues [8–11]. Patient care-seeking delays are well documented [12–16], and treatment delays may also be related to the diagnostic process following the patient’s first presentation with signs and symptoms [9,12,13,17–19].

    • Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes

      2022, Lung Cancer
      Citation Excerpt :

      For disease stage at diagnosis, a similar pattern was found: most studies in each review demonstrated either no association or a negative association (i.e. longer intervals were associated with earlier stage disease) [20,22,25,28,30]. Table A.2 presents detailed results on the direction of association between interval duration with survival or lung cancer stage from the 35 primary studies [38–72] reported across the five included reviews [20,22,25,28,30]. Further summarised results of each review and primary study are presented in Table A.3.

    View all citing articles on Scopus

    Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

    This work was performed at the Veterans Affairs Palo Alto Health Care System. The opinions expressed are those of the authors and not necessarily those of the Department of Veterans Affairs.

    The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

    View full text